Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia
Biz Wire Express,
GlobeNewswire 2022-01-06 MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc.
GlobeNewswire 2022-01-06 MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc.
MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate…
MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that…
Halaven® (eribulin) injection is indicated for the treatment of adult patients with locally advanced or metastatic breast…
MONTREAL, CANADÁ--(BUSINESS WIRE)--A Knight Therapeutics Inc. (TSX:GUD) (“Knight” ou “a Empresa”) anunciou hoje que sua…
MONTREAL, CANADÁ--(BUSINESS WIRE)--Knight Therapeutics Inc. (TSX:GUD) (“Knight” o “la Empresa”) anunciaron hoy que su filial…
MONTREAL, Jan. 06, 2022 Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian…
The Food and Drug Administration has approved the first ever drug for a rare subset of a type of gastrointestinal tract cancer.